有机锡9-芴酮-4-甲酸酯的合成、结构及抗癌活性

合成了 3 个有机锡 9-芴酮-4-甲酸酯:三苯基锡 9-芴酮-4-甲酸酯[(C₆H₅)₃Sn(C₁₄H₇O₃)] (1)、三环己基锡 9-芴酮-4-甲酸酯[(C₆H₁₁)₃Sn(C₁₄H₇O₃)] (2)和三(2-甲基-2-苯基丙基)锡 9-芴酮-4-甲酸酯[(C₆H₅C(CH₃)₂CH₂)₃Sn(C₁₄H₇O₃)] (3)。通过元素分析、红外光谱、核磁共振谱(¹H、¹³C和 ¹¹⁹Sn)、热重分析进行了表征;用单晶X射线衍射方法测定了化合物的晶体结构,并对其进行了量子化学计算和体外抗癌活性研究。结果显示:化合物1为一维链状结构,中心锡原子为五配位的畸变三角双锥构型;化合物2和3均为单核分子,锡原子均为四配位的畸变四面体构型。化合物对人宫颈癌细(HeLa)、人肝癌细胞(HUH-7)、人非小细胞肺癌细胞(A549)、人肺腺癌细胞(H1975)和人乳腺癌细胞(MCF-7)都有较好的抑制活性。     

含扑酸的三烃基锡配合物的合成及结构研究

用扑酸(H₂pa,2,3-diphenylpropionicacid)和三烃基锡氯化物R₃SnCl(R=Ph,Bu,Me)合成了3个有机锡配合物{[(Ph₃Sn)(pa)]·Et₃N}_n(1)、(Bu₃Sn)₂(pa)(2)和[(Me₃Sn)₂(pa)]·CH₂Cl₂(3)。通过元素分析、红外光谱、核磁共振谱及X-ray单晶衍射等手段对配合物进行了表征。结构表明三苯基锡扑酸酯为一维链状聚合物,扑酸作为桥联配体链接各个锡原子,中心锡采取五配位的三角双锥构型;而三甲基锡和三丁基锡扑酸酯配合物为二核锡配合物,锡采取四配位的四面体构型。     

烃基取代茚基钌羰基化合物的合成及晶体结构

配体C₉H₇R(R=CH₂CH₂CH₃ (1),CH₂(CH₃)₂ (2),C₅H₉ (3),CH₂C₆H₅ (4),CH₂CH=CH₂ (5))分别与Ru₃(CO)12在二甲苯或庚烷中加热回流,得到了6个双核配合物[(η⁵-C₉H₆R)Ru(CO)(μ-CO)]₂(R=CH₂CH₂CH₃ (6),CH₂(CH₃)₂ (7),C₅H₈ (8),CH₂C₆H₅ (9),CH₂CH=CH₂ (10))和[(η⁵-C₉H₆)(H₃CH₂C)CHCH(CH₂CH₃)(η⁵-C₉H₆)] [Ru(CO)(μ-CO)]₂ (11).通过元素分析、红外光谱、核磁共振氢谱对配合物的结构进行了表征,并用X-射线单晶衍射法测定了配合物6,9,10和11的结构.     

三个有机锡2，2''-联苯二甲酸酯的微波溶剂热合成、结构及体外抗癌活性

以 2,2''-联苯二甲酸(H₂DPA)分别与双(三(2-甲基-2-苯基丙基)锡)氧化物、三环己基氢氧化锡和二丁基氧化锡反应,合成了3个有机锡2,2''-联苯二甲酸酯：[((PhC(Me)₂CH₂)₃Sn)₂(DPA)] (1)、[(Cy)₃Sn(DPA)]_n (2)和[(n-Bu)₂Sn(DPA)]_n (3)。通过IR、NMR、元素分析、热重及X射线单晶衍射对配合物进行表征分析。配合物1、2、3均属单斜晶系,配合物1为双核结构,配合物2、3为一维链状结构,锡原子的配位数依次增大,分别为4、5、6。体外抗癌活性实验表明,配合物1、2、3对人肺癌细胞(NCI-H460)、人乳腺腺癌细胞(MCF-7)、人肝癌细胞(HepG2)的增殖具有较强的抑制作用。     

二茂铁羧酸及含氮配体构筑的锌(II)和镉(II)配合物的合成、晶体结构及电化学性质

使Zn(OAc)₂·2H₂O或Cd(OAc)₂·2H₂O与邻羧基苯甲酰二茂铁钠(o-OOCC₆H₄COFcNa；Fc=(η⁵-C₅H₅)Fe(η⁵-C₅H₄))和1，10-邻菲咯啉(phen)在甲醇中反应，合成了含有混合配体的单核配合物[Zn(o-OOCC₆H₄COFc)₂(phen)(H₂O)]·CH₃OH (1)和双核配合物{[Cd(η²-o-OOCC₆H₄COFc)( μ₂-o-OOCC₆H₄COFc)(phen)]·CH₃OH₂·H₂O}₂ (2)。晶体结构表明：在1中，单核的结构单元通过分子间氢键形成了一维的长链结构；在2中，o-FcCOC₆H₄COO^-以及phen均双齿螯合中心Cd(II)离子，随后在o-FcCOC₆H₄COO^-的双齿桥联下，形成一个双核结构。研究了这2个配合物在DMF溶液中的电化学性能。     

两个有机锡杂环羧酸酯配合物的合成、结构及抗癌活性

合成了2个有机锡杂环羧酸酯配合物：二（邻溴苄基）锡二（2-吡啶甲酸）酯（1）和三（2-甲基-2-苯基丙基）锡3-吲哚丁酸酯（2）。通过元素分析、红外光谱、核磁共振谱（¹H、¹³C和¹¹⁹Sn）、X射线衍射、热重分析进行了表征,用X射线单晶衍射方法测定了配合物的晶体结构,进行了配合物的结构量子化学从头计算和体外抗癌活性研究。结果显示：配合物均为单锡核分子,锡原子分别为六配位的畸变八面体构型和四配位的畸变四面体构型;配合物对人肝癌细胞（HUH7）、人肺癌细胞（A549）、人表皮癌细胞（A431）、人结肠癌细胞（HCT-116）和乳腺癌细胞（MDA-MB-231）的抑制活性均比临床使用的顺铂强。     

3-苯氧基甲基-4-(4-甲基苯基)-5-(2-吡啶基)-1,2,4-三唑的铜(Ⅱ)、镉(Ⅱ)配合物的合成、晶体结构和光学性质

以3-苯氧基甲基-4-(4-甲基苯基)-5-(2-吡啶基)-1,2,4-三唑(L)为配体分别合成了2个金属配合物即[Cu₂L₂Cl₄]·2H₂O (1)和 [Cd₃L₂(μ₂-Cl)₆]_n·2nCH₃CN (2),对其进行了红外、紫外、热重、粉末衍射、元素分析和晶体结构等表征.配合物 1 和 2 都属于三斜晶系,空间群都为P1 ,单晶结构分析表明,在配合物 1 中,中心铜(Ⅱ)原子具有畸变三角双锥构型[CuN₃Cl₂];配合物 2 是配位聚合物,每个重复单元有3个Cd(Ⅱ)原子和2个不同的Cd(Ⅱ)配位中心,Cd1(Ⅱ)原子具有中心对称的畸变八面体构型CdCl₄N₂,Cd2(Ⅱ)原子具有畸变的八面体构型CdCl₄N₂.     

氨·二甲胺·羧酸根合铂(Ⅱ)类配合物的合成、抗肿瘤活性和与DNA的键合水平

本工作设计合成了6种新型混胺羧酸根合铂(Ⅱ)类配合物[Pt((?)NH)(NH₃)X₂](a～f){其中，X=CH₃COO^-(乙酸根)，CH₃Cl COO^-(氯乙酸根)，CHCl₂COO^-(二氯乙酸根)，C₆H₅-COO^-(苯甲酸根)，p-CH₃-C₆H₄-COO^-(对甲基苯甲酸根)，p-CH₃O-C₆H₄-COO^-(对甲氧基苯甲酸根)}。通过元素分析、摩尔电导、差热分析、红外光谱、紫外光谱和 ¹H核磁共振谱对配合物进行了表征。通过MTT法研究了配合物的体外抗肿瘤活性，通过等离子体质谱研究了配合物与细胞DNA的键合量；体外抗肿瘤活性测试表明，配合物(a～f)对所测试的肿瘤细胞MCF-7、HCT-8和BGC-823没有表现出活性，但对EJ和HL-60两种肿瘤细胞表现出好的活性，而且配合物(d～f)对HL-60细胞的活性与顺铂相当。配合物(a～f)与HL-60细胞的DNA键合量与其作用浓度表现出一定的依赖性，从小到大的顺序为：cisplatin < c < b < a < f < e < d。     

对乙酰氨基苯甲酸和含氮配体构筑铜、锌配合物的合成、结构及性质研究

利用对乙酰氨基苯甲酸（HPABA）和邻菲咯啉（phen）、硝酸铜在DMF/CH₃OH/H₂O溶液中合成了单核铜配合物[Cu（PABA）（phen）（H₂O）₂]·（NO₃）·H₂O（1）,然后又和4,4’-联吡啶（4,4’-bpy）、硝酸锌在DMF/CH₃OH/H₂O溶液中获得配位聚合物{[Zn（PABA）₂（4,4’-bpy）]·4H₂O}_n（2）。根据X射线衍射分析结果,配合物1中每个铜离子周围有2个氮原子和3个氧原子与之配位形成畸变的四方锥配位构型,然而在配合物2中,六配位八面体构型的锌离子通过配体4,4’-联吡啶扩展为一维Zigzag型链。分别对这两个配合物的热稳定性和电化学性质进行了研究。     

二烃基锡萘氧乙酸酯的合成、表征和{[(n-C4H9)2Sn(OOCCH2OC10H7)]2O}2的晶体结构

利用二烃基氧化锡和α-萘氧乙酸按1∶1反应，合成了8种新的有机锡化合物,{[(n-C₄H₉)₂Sn(OOCCH₂OC₁₀H₇)]₂O}₂(R= ⁿBu 1，2-ClC₆H₄CH₂ 2，3-ClC₆H₄CH₂ 3，4-ClC₆H₄CH₂ 4，2-FC₆H₄CH₂ 5，3-FC₆H₄CH₂ 6, 4-FC₆H₄CH₂ 7, 4-NCC₆H₄CH₂ 8)。用元素分析、IR、 ¹H NMR对其结构进行了表征,并测定了化合物{[(n-C₄H₉)₂Sn(OOCCH₂OC₁₀H₇)]₂O}₂ (1)的晶体结构。该化合物晶体属三斜晶系,空间群P1,a=11.974(7) nm，b=1.360 5(9) nm，c=1.386 5(9) nm，α=103.940(9)°，β=104.876(8)°，γ=99.807(9)°，Z=1，V=2.053(2) nm³，D_c=1.431 Mg·m^-3，μ=1.261 mm^-1，F(000)=900，S=1.004，R₁=0.061 0，wR₂=0.151 9。结果表明，化合物1是以Sn₂O₂为中心的中心对称二聚体结构，内环锡和外环锡原子均为五配位的畸变三角双锥构型。     

有机锡9-芴酮-4-甲酸酯的合成、结构及抗癌活性

合成了3个有机锡9-芴酮-4-甲酸酯:三苯基锡9-芴酮-4-甲酸酯[(C₆H₅)₃Sn(C₁₄H₇O₃)](1)、三环己基锡9-芴酮-4-甲酸酯[(C₆H₁₁)₃Sn(C₁₄H₇O₃)](2)和三(2-甲基-2-苯基丙基)锡9-芴酮-4-甲酸酯[(C₆H₅C(CH₃)₂CH₂)₃Sn(C₁₄H₇O₃)](3)。通过元素分析、红外光谱、核磁共振谱(¹H、¹³C和¹¹⁹Sn)、热重分析进行了表征;用单晶X射线衍射方法测定了化合物的晶体结构,并对其进行了量子化学计算和体外抗...     

Synthesis and crystal structure of diorganotin(IV) complexes with pyruvic acid benzoylhydrazone and pyruvic acid salicylhydrazone

Six diorganotin esters of Schiff-base ligands formulated as [R₂SnLY]₂, where L₁ is C₆H₅CON₂C(CH₃)CO₂ with Y?=?CH₃CH₂OH, R?=?mClC₆H₄CH₂ (1), oFC₆H₄CH₂ (2), pFC₆H₄CH₂ (3) and L₂ is 2-HOC₆H₄CON₂C(CH₃)CO₂ with Y?=?CH₃OH, R?=?oFC₆H₄CH₂ (4), pFC₆H₄CH₂ (5), mClC₆H₄CH₂ (6) have been prepared and characterized by elemental analysis, IR, ¹H and ¹¹⁹Sn NMR spectra. The crystal structures of complexes 1 and 4 have been determined by X-ray single crystal diffraction. The structure analyses reveal that the Sn atom in both 1 and 4 is seven-coordinate in distorted pentagonal bipyramid geometries with a planar SnO₄N unit and two apical aryl carbon atoms, thus forming a dimeric molecule, which sits on a crystallographic center of symmetry. Intramolecular or intradimeric hydrogen bonds contribute to the stability and compactness of the crystal structures.     

四个基于酰腙配体的双核苄基锡配合物的合成、晶体结构及体外抗癌活性

通过微波"一锅法"合成了4个双核苄基锡配合物:{[C_4H_3S(O)C=N-N=C(Me)COO](PhCH_2)_2Sn(MeOH)}_2(C1)、{[C_4H_3S(O)C=NN=C (Me)COO](p-Cl-C_6H_4CH_2)_2Sn (MeOH)}_2(C2)、{[C_4H_3S (O)C=N-N=C (PhCH_2)COO](PhCH_2)_2Sn (MeOH)}_2(C3)、{[C_4H_3S (O)C=N-N=C(PhCH_2)COO](p-Cl-C_6H_4CH_2)_2Sn(MeOH)}_2(C4),利用元素分析、IR、~1H NMR、~(13)C NMR、~(119)Sn NMR、HRMS以及X射线单晶衍射等表征了配合物结构。4个配合物分子均为双锡核分子,以Sn_2O_2四元环为中心对称,且中心锡原子与配位原子形成七配位畸变五角双锥构型。测试了配合物C1～C4的热稳定性以及配合物对癌细胞H460、HepG2、MCF7的体外抑制活性,结果表明:配合物C2是4个新合成的配合物中抑制癌细胞效果最好的化合物。     

Syntheses,crystal structures and biological activity of the dialkytin complexes based on 2-oxo-3-phenylpropionic acid salicyloylhydrazone

Three new dialkytin complexes, {[o-OH–C₆H₄(O)C=N–N=C(CH₂Ph)COO](n-Bu₂Sn)}_n (1), {[o-OH–C₆H₄(O)C=N–N=C(CH₂Ph)COO](MeOH)(p-MeC₆H₅CH₂)₂Sn}₂ (2), and {[o-OH–C₆H₄(O)C=N–N=C(CH₂Ph)COO](EtOH)(C₆H₅CH₂)₂Sn}₂ (3), were synthesized by reactions of 2-oxo-3-phenylpropionic acid salicyloylhydrazone with the corresponding diorganotin(IV) complex, respectively. All the complexes were characterized by IR, ¹H, ¹³C, ¹¹⁹Sn NMR spectra, elemental analysis, X-ray single crystal diffraction and TGA. For in vitro antitumor activities, complexes were evaluated by the MTT assay against three human cancer cell lines (NCI-H460, HepG2 and MCF7) and human cell line (HL7702). The results showed that 1 may be a better potential candidate for further chemical optimization and cancer therapy than 2 and 3. The interactions between the complexes and calf thymus DNA were studied; the interaction of 1 with calf thymus DNA was intercalation, 2 and 3 were intercalation and electrostatic binding.     

Syntheses and structures of two new uranyl complexes [UO2(DPDPU)2(NO3)2](C6H5CH3) and [UO2(PMBP)2(DPDPU)](CH3C6H4CH3)0.5

Two new uranyl complexes [UO₂(DPDPU)₂(NO₃)₂](C₆H₅CH₃) (1) and [UO₂(PMBP)₂ (DPDPU)](CH₃C₆H₄CH₃)_0.5 (2), (DPDPU?=?N,N′-dipropyl-N,N′-diphenylurea, HPMBP?= 1-phenyl-3-methyl-4-benzoyl-pyrazolone-5) were synthesized and characterized. The coordination geometry of the uranyl atom in 1 is distorted hexagonal bipyramidal, coordinated by two oxygen atoms of two DPDPU molecules and four oxygen atoms of two bidentate nitrate groups. The coordination geometry of the uranyl atom in 2 is distorted pentagonal bipyramidal, coordinated by one oxygen atom of one DPDPU molecule and four oxygen atoms of two chelating PMBP molecules.     

The in vitro antifungal activity of some dithiocarbamate organotin(IV) compounds on Candida albicans— a model for biological interaction of organotin complexes

The in vitro antifungal activity of the dithiocarbamate organotin complexes [Sn{S₂CN(CH₂)₄}₂Cl₂] ( 1 ), [Sn{S₂CN(CH₂)₄}₂Ph₂] ( 2 ), [Sn{S₂CN(CH₂)₄}Ph₃] ( 3 ), [Sn{S₂CN(CH₂)₄}₂n‐Bu₂] ( 4 ), [Sn{S₂CN(CH₂)₄}Cy₃] {Cy = cyclohexyl} ( 5 ), [Sn{S₂CN(C₂H₅)₂}₂Cl₂] ( 6 ), [Sn{S₂CN(C₂H₅)₂}₂Ph₂] ( 7 ), [Sn{S₂CN(C₂H₅)₂}Ph₃] ( 8 ), [Sn{S₂CN(C₂H₅)₂}₃Ph] ( 9 ) and [Sn{S₂CN(C₂H₅)₂}Cy₃] ( 10 ) has been screened against Candida albicans (ATCC 18804), Candida tropicalis (ATCC 750) and resistant Candida albicans collected from HIV‐positive Brazilian patients with oral candidiasis. All compounds exhibited antifungal activities and complexes 3 and 8 displayed the best results. We have investigated the effect of compounds 1–10 on the cellular activity of the yeast cultures. Changes in mitochondrial function have not been detected. However, all drugs reduced ergosterol biosynthesis. Preliminary studies on DNA integrity indicated that the compounds do not cause gross damage to yeast DNA. The data suggest that these compounds share some mechanisms of action on cell membranes similar to that of polyene but not with azole drugs, normally used in Candida infections. Copyright © 2008 John Wiley & Sons, Ltd.     

Organoselenium compounds containing pyrazole or phenylthiazole groups: Synthesis,structure, tin(IV) complexes and antiproliferative activity

The diorganodiselenides (pzCH₂CH₂)₂Se₂ ( 1 ) and (PhtzCH₂)₂Se₂ ( 2 ) were prepared by reacting Na₂Se₂ with 1‐(2‐bromoethyl)‐1H‐pyrazole and 4‐(chloromethyl)‐2‐phenylthiazole, respectively, while the reactions between 1‐(2‐bromoethyl)‐1H‐pyrazole or 4‐(chloromethyl)‐2‐phenylthiazole and the lithium organoselenolates [2‐(Et₂NCH₂)C₆H₄]SeLi and [2‐{O(CH₂CH₂)₂NCH₂}C₆H₄]SeLi in a 1:1 molar ratio resulted in the heteroleptic diorganoselenium(II) compounds [2‐(Et₂NCH₂)C₆H₄](R)Se (R = pzCH₂CH₂ ( 3 ) or PhtzCH₂ ( 5 )) and [2‐{O(CH₂CH₂)₂NCH₂}C₆H₄](R)Se (R = pzCH₂CH₂ ( 4 ) or PhtzCH₂ ( 6 )). The diorganotin(IV) bis(organoselenolato) derivatives of type R₂Sn(SeCH₂CH₂pz)₂ (R = 2‐(Me₂NCH₂)C₆H₄ ( 7 ) or Me ( 8 )) were obtained by reacting (pzCH₂CH₂)SeNa with the appropriate diorganotin(IV)dichloride in a 2:1 molar ratio. All compounds were investigated using NMR spectroscopy (¹H, ¹³C, ⁷⁷Se, ¹¹⁹Sn as appropriate) and ESI+ mass spectrometry. The molecular structures of 2 and 6 were determined using single‐crystal X‐ray diffraction. The formation of a 10–Se–3 hypercoordinated species was evidenced for 6 in the solid state, as a consequence of the C,N coordination behaviour of the 2‐{O(CH₂CH₂)₂NCH₂}C₆H₄ group. Compounds 1 , 7 and 8 were investigated for their antiproliferative activity towards the mouse colon carcinoma C26 cell line with the preliminary results showing a better activity than 5‐fluorouracil.     

Coordination behaviour of the 2‐(N,N‐dimethylaminomethyl)phenyl ligand towards the di‐t‐butylchlorotin(IV) moiety

{2‐(N,N‐Dimethylaminomethyl)phenyl}(di‐t‐butyl)tin(IV)chloride, {2‐[(CH₃)₂NCH₂]C₆H₄}Sn(t‐Bu)₂ Cl, has been prepared and characterized using NMR and crystallography. This is the first example of a triorganotin(IV) halide containing the 2‐[(CH₃)₂NCH₂]C₆H₄—group as a C,N‐chelating ligand with a weak intramolecular Sn—N interaction because of the steric hindrance of t‐butyl groups. The interatomic Sn—N distance is elongated to 2.904(14) Å and the central tin atom is distorted trigonal bipyramidal. Copyright © 2004 John Wiley & Sons, Ltd.